Ocugen, INC Form 4 insider transactions

Ocugen, Inc. Chief Financial Officer Treerita Johnson-Greene acquired 21,000 shares of common stock on June 15, 2026.

Ocugen, Inc. Director Kompella Uday was granted stock options for 170,100 shares of common stock.

Ocugen, Inc. reports that Director Chandrasekhar Satishchandran acquired stock options, indicating a potential long-term commitment to the company.

Ocugen, Inc. reports that Director Kirsten Castillo was granted stock options to purchase 170,100 shares of common stock at an exercise price of $1.22 per share.

Ocugen, Inc. reports that Director Zhang Junge acquired stock options for 170,100 shares of common stock.

Ocugen, Inc. reports that Director Blaise Coleman was granted stock options for 170,100 shares with an exercise price of $1.22.

Ocugen, Inc. reports that Director Zhang Junge acquired a significant number of common shares through the exercise of stock options on April 1, 2026.

Ocugen, Inc. CEO Shankar Musunuri received a significant grant of performance stock units and stock options, aligning executive incentives with future company performance.

Ocugen's Chief Accounting Officer, Ramesh Ramachandran, was granted 207,300 restricted stock units and options to purchase 310,950 shares of common stock.

Ocugen, Inc. director Satishchandran Chandrasekhar was granted 151,316 stock options with an exercise price of $0.95, vesting over three years.

Ocugen, Inc. Director Blaise Coleman has been granted 151,316 stock options with an exercise price of $0.95, vesting monthly over three years starting July 5, 2025.

Ocugen, Inc. director Kirsten Castillo was granted 151,316 stock options with an exercise price of $0.95, vesting over approximately one year.

Ocugen, Inc. Director Uday Kompella was granted 151,316 stock options with an exercise price of $0.95, vesting upon the earlier of June 5, 2026, or the next annual meeting.

Ocugen, Inc. Director Junge Zhang was granted 151,316 stock options with an exercise price of $0.95, aligning his interests with shareholder value.

Ramesh Ramachandran, Ocugen's Chief Accounting Officer, reports the acquisition of options to purchase 350,146 shares of common stock.

Arun Upadhyay, Chief Scientific Officer of Ocugen, Inc., acquired options to purchase 730,994 shares of common stock and disposed of 41,633 shares to cover tax obligations.

Ocugen's CEO, Shankar Musunuri, reports the acquisition of stock options and a disposition of shares to cover tax obligations.

Huma Qamar, Ocugen's Chief Medical Officer, reported the acquisition of options to purchase 1,145,468 shares of common stock.

Ocugen director Prabhavathi Fernandes purchased 10,000 shares of the company's common stock at an average price of $0.9095 on November 26, 2024.

Ocugen director Kirsten Castillo purchased 25,000 shares of common stock at a weighted average price of $0.9139 per share.

Arun Upadhyay, Chief Scientific Officer of Ocugen, Inc., disposed of 842 shares of common stock on September 16, 2024, to cover tax obligations.

Marna Whittington, a director at Ocugen, Inc., acquired options to purchase 66,929 shares of common stock at an exercise price of $1.55 on June 28, 2024.

Director Uday Kompella acquired options to purchase 66,929 shares of Ocugen, Inc. common stock.

Director Kirsten Castillo acquired options to purchase 66,929 shares of Ocugen, Inc. common stock at an exercise price of $1.55 on June 28, 2024.

Director Zhang Junge acquired options to purchase 66,929 shares of Ocugen, Inc. common stock.

Director Prabhavathi Fernandes acquired options to purchase 66,929 shares of Ocugen, Inc. common stock on June 28, 2024.

Ocugen's Chief Scientific Officer, Arun Upadhyay, disposed of 917 shares of common stock to cover tax obligations.

Huma Qamar, Chief Medical Officer of Ocugen, Inc., reports the acquisition of stock options.